drugset / Trial / NCT02713789
Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for ED
Phase 2
Completed
26 enrolled
Urovant Sciences GmbH
Dasman Diabetes Institute · collabIon Channel Innovations · collab
RandomizedParallel-groupDouble-blindOther
Summary
To evaluate the safety and efficacy of a single intracavernous injection of hMaxi K (8000 µg and 16000 µg) or placebo upon penile rigidity or erection in males with erectile dysfunction longer than six months that is attributable to an underlying, stable medical condition.
Timeline
- Start
- 2015-04
- Primary completion
- 2017-08-24
- Completion
- 2017-08-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | hMaxi-K | Gene therapy (AAV / viral vector) | 8000 ug | Other |
| Comparator | hMaxi-K | Gene therapy (AAV / viral vector) | 16000 ug | Other |